Objective: Neurocognitive disorders are devastating consequences of HIV infection. Although antiretroviral regimens have been efficacious in both improving life expectancy and decreasing dementia, there has not been an effect on the overall prevalence of HIV-associated neurocognitive disorders. Whether early institution of treatment, or treatment with drugs that effectively penetrate the blood-brain barrier, would help protect from such conditions is not known. Using the simian immunodeficiency virus/ macaque model, we investigated the hypothesis that early introduction of antiretroviral treatment can protect the brain.
Introduction
A high proportion of HIV-1-infected individuals develop alterations in neurocognition (referred to as HIVassociated neurocognitive disorders; HAND), which are most prominent at later phases of infection. In the current era of HAART, the incidence of the severe form, HIV-1-associated dementia (HAD) has decreased [1] ; however, other, less severe conditions persist. With the treatment-induced longer life expectancy, the prevalence of central nervous system (CNS) complications has risen in comparison with other AIDS-related complications, and as a whole, is either unchanged or possibly increasing [2] [3] [4] [5] [6] . There are many proposed reasons for this such as viral mutation, failure of therapy, CNS immunopathology due to the virus-host interaction, and/or lack of blood-brain barrier (BBB) penetration of therapy. Although the role of brain-penetrating antiretroviral agents in general HIV therapy is not clear, it has been found that the use of drugs thought to have higher CNS penetration or activity are associated with lower cerebrospinal fluid (CSF) viral loads [7, 8] .
Although the exact mechanism of HAND is not known, HIV infection of the CNS clearly initiates the disease. Macrophages and microglia are the only productively infected cells in the CNS, and thus, an indirect neurotoxic effect has been suggested [9] . Viral proteins, products of infected and/or activated microglia and macrophages, intrathecal immunoactivation, accumulation, and persistency of immune cells in the brain parenchyma, are probably also part of the pathogenesis and neurodegenerative process.
Simian immunodeficiency virus (SIV) infection in rhesus macaques reproduces all aspects of human infection with
HIV, including the development of neurocognitive disorders [10, 11] . Neurophysiological testing has revealed that changes in CNS function are detectable early after infection [12, 13] . This is attributed to the early presence of the virus in the CNS, triggering events that can lead to neuronal damage. Among the alterations in the brain tissue in the SIV model, infiltrating immune cells, predominantly CD8 þ T cells, are detectable early after infection and persist within the CNS [13] . These accumulating CD8 cells are in a highly activated state, based on the expression of surface activation markers and transcription of cytolytic and proinflammatory cytokines, and a high proportion of them are specific to the virus [14] .
In addition to neurophysiological changes, we have found that SIV infection results in changes in the regulation of temperature and movement as well as alterations in cognitive and motor function [15] [16] [17] . To examine the role of treatment in the reversal of early identifiable changes in CNS function, we had previously examined the effects of antiretroviral therapy using monotherapy with 9-[2-(R)-(phosphonomethoxy) propyl]adenine (PMPA, tenofovir). This treatment (which was instituted following the identification of such abnormalities) was indeed able to reverse neurophysiological abnormalities, and following cessation of treatment, they returned [12] . However, the general decrease in locomotor activity was not responsive to this regimen.
Yet, little is known about the HIVor SIV-infected brain in the setting of antiretroviral therapy. Indeed, where infected individuals have access to such treatment, this is the most common state of the CNS in HIV infection. In order to address the effects of antiretroviral therapy on the brain, we report here studies on two groups of SIV-infected animals -one receiving combination antiretroviral therapy (the reverse transcriptase inhibitor tenofovir as well as the protease inhibitor nelfinavir) and the other receiving placebo as a control. Neither of these agents are clinically considered efficacious in the CNS [7, 8, 18] . Although our earlier study [12] examined the brains after cessation of monotherapy, here, animals were sacrificed while on active combination therapy (or placebo) to assess changes in the brain environment during treatment.
Methods Animals
Rhesus monkeys, free from SIV, type D simian retrovirus, and herpes B virus, were obtained from Covance (Alice, Texas, USA) and Charles River (Key Lois, Florida, USA). All animal experiments were performed with approval from the Scripps Institutional Animal Care and Use Committee and followed National Institutes of Health (NIH) guidelines. Blood samples were drawn from the femoral vein from animals under ketamine anesthesia, and plasma was separated by centrifugation from cells in EDTA-anticoagulated blood. CSF was obtained from the cisterna magna. CSF samples containing more than 0.1% blood contamination [determined by red blood cell (RBC) counts] were discarded. Necropsy was performed after terminal anesthesia. During necropsy, animals were perfused intracardially with sterile PBS containing 1 U/ml heparin before tissue samples were taken for cell isolation, virus quantification, and formalin fixation for histology.
Radiotelemetry
Body temperature and gross locomotor activity were measured by means of radiotelemetry implants, placed while the animals were under isoflurane anesthesia, with postoperative analgesia with buprenorphine. Signals from individually implanted telemetry transmitters (Physiotel TA10TA-D70; Data Sciences International, St. Paul, Minnesota, USA) were received by individual receivers (model RMC-1; Data Sciences International), which were connected to the data acquisition matrix, and the data were processed using Dataquest ART 4.0 software (Data Sciences International). Temperature and activity were continuously monitored before and after infection. The values used for this study correspond to the average of 12-h daytime recording periods.
Viral infection
A cell-free stock of SIV (derived from SIVmac251) obtained after serial passage of SIV-infected microglia was the inoculum used [19] . Animals received 0.25 ml of the stock, diluted into Roswell Park Memorial Institute (RPMI)-1640 (Invitrogen, Carlsbad, California, USA) for intravenous injection, containing 5 ng/ml of p27 (gag) antigen.
Antiviral treatment
Antiretroviral-treated animals received one daily intramuscular injection of tenofovir (Gilead, Foster City, California, USA), 30 mg/kg in phosphate-buffered physiological saline, at 1130 h, and nelfinavir mesylate (Pfizer, New York, New York, USA) was administered orally at 20 mg/kg in banana-flavored primate tablets (Bio-Serve, Frenchtown, New Jersey, USA), twice a day, at 0600 and at 1600 h. The treatment was initiated at 8 weeks after SIV inoculation and lasted until termination. Animals with numbers 422, 424, 492, and 495 were treated with placebo (placebo injections and pills), whereas animals with numbers 425, 431, 433, and 498 received the active agents. All animals were sacrificed between 15 and 16 weeks after SIV inoculation while still receiving the treatment per experimental protocol.
Viral quantitation
To measure viral load, SIV RNA in plasma, CSF, and brain tissue, quantitative branched DNA signal amplification assay was performed by Siemens Reference Testing Laboratory (Emeryville, California, USA). Each sample was measured in duplicate and reported as average value.
Electrophysiology
Electrophysiological analysis of brainstem auditory evoked potential (BSAEP) was performed on ketamine (20 mg/kg)-anesthetized animals as described previously [20] . Averaged peak latencies were calculated and compared between group means.
Peripheral mononuclear cells
Buffy coats obtained from centrifugation of EDTAanticoagulated blood, and cell suspensions from spleen, deep cervical, and inguinal lymph nodes, passed through a nylon mesh, were submitted to a Ficoll-isopaque (Pharmacia Biotech, Uppsala, Sweden) gradient centrifugation for isolation of the mononuclear fraction. After washing, cells were enumerated in a Coulter Z2 (Coulter Co., Miami, Florida, USA) and resuspended in complete RPMI-1640, containing 10% fetal calf serum (FCS) at a concentration of 10 7 /ml, for labeling or cryopreservation.
Brain cells
The meninges were carefully removed and the brain mechanically and enzymatically disassociated, and immune cells purified on a Percoll gradient (Pharmacia Biotech) as previously described [13] and quantified in a Coulter Z2. 
Real time PCR
For RNA extraction, total RNAwas purified from samples using TRIzol reagent (Invitrogen, Carlsbad, California, USA) following the protocol of the manufacturer, with an additional centrifugation step to remove cellular debris. RNA was further purified (RNeasy mini kit; Qiagen, Valencia, California, USA) and quantified by 260 nm ultraviolet (UV) absorption. Specific RNA transcripts were quantified using real-time PCR. The primers and probe sequences for b-2-microglobulin (b2M), chemokine ligand 5 (CCL5), G1P3, human leukocyte antigen (HLA)-DRa, interleukin (IL)-15, IL-1b, and tumor necrosis factor-a (TNFa), and the control genes 18S, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and TATA box-binding protein (TBP) were designed for rhesus macaque sequences and were previously reported [14, 21, 22] . The primers and probe sequences for interferon-a (IFN-a) were homologous to rhesus IFN-a2 and were: (forward primer) GCCTGAAGGA-CAGACATGACTTT, (reverse primer) GGATGGTT-TGAGCCTTTTGG, (FAM/TAMRA-labeled probe) CCCCAGGAGGAGTTTGGCAACCA. Relative amounts of each cytokine mRNA in the samples was obtained upon normalization of the average cycle threshold (Ct) against the average of the three control genes. Reactions were performed in a Stratagene MX30000 (Stratagene, La Jolla, California, USA).
Statistical analysis
Statistical analysis was done using Student's t-test or analysis of variance (ANOVA), followed by a posttest when appropriate. Alpha was set at 0.05 for determination of significance. The tests were performed using Microsoft Excel X for Mac or Prism version 4.0 for Mac (GraphPad Software, La Jolla, California, USA).
Results
Antiretroviral treatment ameliorates sensoryevoked potential abnormality and decreases brain viral load Plasma viral load dropped as a result of the treatment in all four treated animals as compared to both pretreatment levels of viremia and to those found in the control animals that received placebo, throughout the treatment, and until termination (Fig. 1a) . In three of the treated animals, the plasma viral load dropped to below the limit of detection, whereas the fourth reached levels near the limit of detection. Although CSF was not sampled as frequently as blood, in all four of the antiretroviral-treated animals, the CSF viral load dropped below the limit of detection following treatment compared with just one of the four control animals.
Changes in viral load did not correlate with changes on the relative or absolute numbers of either CD4 or CD8 T cells (data not shown) in the blood, and such T-cell numbers did not differ significantly between the groups. The treatment regimen did prevent the neurophysiological changes induced by infection, measured as a delay in late wave (P5) of the BSAEP (Fig. 1b) . After infection, the motor activity began to decrease but returned to baseline following treatment (Fig. 1c) . Although technical problems prevented the analysis of motor activity in the control group, we consistently observe a significant decline in motor activity following infection [12, 17] . Following sacrifice, viral and immune parameters were analyzed in the brain. Treatment was successful in lowering the viral load in the brain (Fig. 2a) . Although the amount of virus was reduced, the number of brain infiltrating CD8
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þ T cells, which were close to four-fold higher than in uninfected animals, did not differ between groups (13 482 AE 4822 CD8 þ cells/uninfected brain; 37 196 AE 3361 CD8 þ cells/placebo-treated brain; and 34 683 AE 10 990 CD8 þ cells/antiretroviral-treated brain) (Fig. 2b) . Similarly, the numbers of CD4 T cells, CD3-CD8 þ natural killer (NK) cells, or CD11b þ cells (microglia and macrophages) in infected brains were similar to the numbers found in uninfected animals for these populations (not shown), and there was no difference in placebo versus antiretroviral-treated animals.
Antiretroviral treatment alters memory T cells in the brain of infected monkeys
In order to assess whether treatment led to differences in immune cell phenotypes, several surface markers that can be altered by cellular activation were evaluated on CD4 and CD8 T cells from the brain, CSF, blood, spleen, and liver. The percentage of CD11a-expressing T cells in infected animals was consistently higher than in uninfected controls (not shown), did not distinguish between infected groups subjected or not to antiretroviral treatment, either in blood, spleen, liver, or in the brain (not shown). However, in the CSF, CD8 cells expressing high levels of CD11a were more abundant in placebotreated animals (84.8 AE 18.4% CD8 T cells) than in antiretroviral-treated animals (48.6 AE 8.2%) (P ¼ 0.016, Student's t-test). Neither chemokine receptor 5 (CCR5) and CD25 [IL-2 receptor (IL-2R)] nor CD122 (IL-15R) was significantly altered by treatment in any of these sites (not shown).
In addition to these T-cell activation markers, we also investigated whether the antiretroviral treatment alters the memory phenotype or the distribution of memory cells. Overall, we observed that surface molecules, which correlate with the memory status, were able to distinguish groups, especially within the CD4 compartment. CD95 expression identifies memory T cells in monkeys [23, 24] . We further divided CD95 þ cells for the expression of CCR7. The down-modulation of this marker within the CD95 þ fraction correlates with the development of an effector memory phenotype [effector memory T-cell (TEM)], whereas cells that remain CCR7 þ play a central memory role [central memory T-cell (TCM)]. The expression of CCR7, within the CD95 þ fraction, was significantly different among CD4 cells in the two nonlymphoid organs, the liver and the brain, between the groups (Table 1 ). In the animals that received antiretrovirals, there is an increase of TEM (cells with lower CCR7 expression) at the expense of TCM (high CCR7 expression) phenotype compared with placebo-treated animals (P ¼ 0.016 and P ¼ 0.005 for brain and liver, respectively, Student's t-test). In the CD8 compartment, There were no significant differences between the groups. ANOVA, analysis of variance; SIV, simian immunodeficiency virus. Thus, the T-cell proportions are altered in the organs of SIV-infected antiretroviral-treated animals compared with those animals that are infected but not treated. Specifically, in the brains of SIV-infected animals, the antiretroviral treatment resulted in a change both in the CD4 and CD8 T-cell compartments characterized by an increase in TEM.
Antiretroviral therapy affects host-response gene expression in the infected brain
The changes in the brain viral load and infiltrating immune cell phenotypes found in treated animals reveal a significant change in the virus/host interaction within the CNS. We have previously found that this can be reflected in the gene expression pattern in the infected brains. In the chronic, stable phase of infection, we identified a number of genes whose expression differed between the brains of uninfected and SIV-infected animals, including those involved in class I and class II antigen presentation (b2M and HLA-DRa), IFN-induced genes, including the antiviral, antiapoptotic molecule G1P3, and the CCL5 [also known as regulated on activation, normal T expressed and secreted (RANTES)] [21] . In addition, in chronically infected animals, we have identified the cytokine IL-15 as elevated in the brain [14] . We, therefore, examined the expression of these genes in the brains of the infected, treated animals as compared with the levels found in the infected, placebo-treated animals' brains.
The expression of two of these genes was modified by the treatment regimen. G1P3 was reduced by treatment, whereas in contrast CCL5 was elevated; the others were not significantly altered (Fig. 3a) . As both of these genes can be responsive to IFN and other inflammatory molecules, we next assessed the expression of IFN-a and IFN-b, as well as TNF-a. Although the levels of IFN-b and TNF-a in the brains were not altered by antiretroviral treatment, the expression of IFN-a was significantly lower in the brains of treated animals (Fig. 3b) . Interestingly, expression of these genes differed across brain regions. In both the control and antiretroviraltreated groups, the mean expression of these molecules was significantly higher in the hippocampus than the other brain regions (two-way ANOVA: P < 0.0001; Bonferroni's posttests: P < 0.05 for both control and treated groups for hippocampus versus frontal, caudate, pons, and occipital).
Discussion
Using an antiretroviral treatment regimen considered clinically to have low CNS efficacy, instituted in SIVinfected animals following the resolution of the acute viremic stage, we confirmed and expanded upon our prior results that a reduction of plasma viral load induced by the therapy is beneficial for preventing/treating CNS dysfunction. Here, modeling an early commencement of treatment, for example after an individual is exposed, develops an acute viremic syndrome, is recognized as infected and begins therapy, we find that treatment leads to a significant reduction in the viral load in the brain. Although the magnitude of the infiltrating immune cells into the brain is unchanged, treatment induces an alteration in the memory phenotypes in the brain as well as a peripheral organ, the liver. Finally, alterations of the host transcriptional response to infection occur, with a decrease in IFN-a and the IFN-responsive G1P3 and an increase in CCL5.
Our studies and those of others reveal that virus enters the brain early and is easily detectable by the second week after inoculation [25] [26] [27] . The RNA viral load then drops in the brain as it does outside of the brain likely due to immune control. The decrease in viral load in the brain that we observed following treatment is likely either due to a lower level of continued infection of the brain from peripheral virus, which itself is markedly diminished, or more effective immune control of the virus within the brain. The overall number of infiltrating immune cells is unchanged by antiretroviral treatment in the infected brain. However, there was an overall enrichment of effector CD4 cells and decline in CD8 TCM. Such a shift in phenotype argues for increased active immune control of virus in the brain or for less killing of target cells. Although we did not quantify the percentage of virusspecific cells, the shifting to an effector phenotype, correlating with a successful decrease of viral load, may contribute to the generation of a more focused response, with less bystander activity, which may be rather beneficial both to control the virus and avoid damage to neuronal components.
Other studies [28] have found that monkeys with chronic SIV infection and treated with antiretrovirals showed changes in the distribution of the memory phenotype within SIV-specific cytotoxic T lymphocytes (CTL) in the blood from TEM to TCM. We did not see such a shift in blood, possibly due to the earlier institution of treatment as well as our examination of bulk CD8 T cells as opposed to viral epitope-specific CTL. In any regard, in the brain, we found the opposite in both CD4 and CD8 T cells, with a shift from TCM to TEM. This shift may represent changes in the brain CD8 population that favor more effective immune control of virus, resulting in the lowered brain viral load. However, the antiretroviral drugs may reduce the brain viral load by controlling virus peripherally. This can result in lowered infection and killing of active TEM cells, thus increasing their frequency. Regardless of the mechanism, the enrichment of effector memory caused by early antiretroviral treatment resembles the phenotype observed in liveattenuated vaccination protocols [29] , suggesting the potential of development of a long-lasting protective environment and priming by reducing the initial set point viral load.
Treatment, and the subsequent lowering of brain and blood virus, resulted in a significant decrease of IFN-a in the infected brain. This finding is a potential key for the amelioration of CNS dysfunction, manifested in HIV infection as cognitive and motor symptoms and in our experiments as abnormal delay in sensory-evoked potentials. Although we cannot exclude a direct effect from the drugs themselves, this is correlated with the decrease of infected cells in the CNS. Increased IFN-a in the basal ganglia in patients has been shown to contribute to neurological and behavioral changes [30] [31] [32] [33] [34] [35] . Patients with HIV dementia have high levels of IFN-a in the CSF [36, 37] . Also, in a mouse model of neuroAIDS, in which HIV-infected macrophages are intracerebrally injected in severe combined immunodeficiency (SCID) mice, cognitive dysfunction correlates with the expression of IFN-a on neurons and glial cells [38, 39] . Interestingly, IFN-a treatment is used therapeutically in some viral infections and cancer, but such treatment often results in neurological deficits and behavioral alterations [40] [41] [42] [43] [44] , strongly suggesting a direct correlation between levels of this cytokine and CNS dysfunction.
IFN-a can also influence the local T-cell response. It supports an effector phenotype on T cells, but by transiently increasing apoptosis also contributes to the elimination of activated cells [45] . In addition, similar to IL-15, IFN-a can support the division of memory cells in an antigen-independent way, facilitating the enrichment of bystander cells [46, 47] . However, whether there is a linkage between the reduction in IFN-a and the changes found in T-cell phenotypes in the brain is not known.
In contrast to the decrease in IFN-a, CCL5 is increased in the brains of treated animals. Whether this increase found with treatment may result from, or possibly contribute to, the difference in T-cell memory phenotype is not known. In addition to its chemokine properties, CCL5 is among the soluble inhibitory factors with the ability to inhibit HIV-1 infection and spread [48] , and thus may contribute to the reduction in brain viral load. Furthermore, CCL5 treatment of microglia was found to reduce their expression of the proinflammatory molecules, thus might act in protecting neurons from their deleterious effects [49] .
Interestingly, the inflammatory mediator profiling revealed that, irrespective of treatment, higher levels of their mRNAs could be found in the hippocampus as opposed to other brain regions. Certainly, regionspecific gene expression occurs in the primate brain [50] , but whether this contributes to these region-specific differences found in the infected brain is unknown. However, it has been found that hippocampal microglia, compared with microglia from other regions of the brain, express higher levels of some inflammatory mediators [51] . Our findings may reflect such increased proclivity of hippocampal microglia to express inflammatory molecules.
Overall, our results reveal the significance of early treatment, even with antiretroviral agents that do not penetrate the BBB. Early administration of antiretrovirals is effective in lowering virus in the brain as well as preventing early signs of CNS dysfunction. Whether such early treatment will be effective in preventing the development of HAND is not known. However, a later introduction of antiretrovirals may not have such a beneficial effect, given the chronicity of virus-host interaction and its resulting effects in the brain. The effect of early treatment on the development of CNS disorders is worthy of study, as both early as well as chronic changes in the brain, including levels of virus and cytokines, can have a profound impact over the course of infection and overall patient prognosis.
